TickerGuard
Buy Day today: Neutral (58) Mixed market breadth · no major macro event
ABOS

Acumen Pharmaceuticals Inc

Healthcare · Biotechnology

0.2235$ +4.5% vs. previous close Closing price · As of: Nov 6, 2026

Ownership

Ownership Structure

Who owns Acumen Pharmaceuticals Inc (ABOS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 51.2% of the shares are freely tradable; institutional investors hold 64.2%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 64.2%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 6.8%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 51.2%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 6.1%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 72Mio.

Largest Shareholders

Institutions

Institutions ABOS
Name Stake (%) Shares Change (%) Date
RA Capital Management, LLC 29.02 20,992,669 +0.0 06/30/2026
Sands Capital Ventures, LLC 5.14 3,720,105 +0.0 06/30/2026
BlackRock Inc 3.44 2,490,115 +1,296.4 06/30/2026
Alyeska Investment Group, L.P. 3.39 2,454,754 +0.0 06/30/2026
Franklin Templeton Inc 3.19 2,305,096 +0.0 06/30/2026
ADAR1 Capital Management LLC 2.92 2,111,334 -2.1 06/30/2026
Vanguard Capital Management, LLC 2.31 1,672,072 +11.0 06/30/2026
Knollwood Investment Advisory LLC 2.25 1,628,510 +0.0 06/30/2026

Funds

Funds ABOS
Name Stake (%) Shares Change (%) Date
Franklin Biotechnology Discv A(acc)USD 2.04 1,478,586 +0.0 09/30/2026
Vanguard MStar Total Stk Mkt Idx Invest 1.75 1,262,692 +12.9 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?